Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study
- PMID: 29446069
- DOI: 10.1002/cpt.1046
Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study
Abstract
The orexin system regulates sleep and arousal and is targeted by ACT-541468, a new dual orexin receptor antagonist (DORA). Healthy male subjects received a single oral dose of 5-200 mg to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), mass balance, metabolism, and absolute bioavailability utilizing a 14 C-labeled, orally and intravenously (i.v.) administered microtracer. The drug was safe and well tolerated; the PK profile was characterized by quick absorption and elimination, with median time to reach maximum concentration (tmax ) of 0.8-2.8 h and geometric mean terminal half-life (t1/2 ) of 5.9-8.8 h. Clear dose-related effects on the central nervous system were observed at ≥25 mg, indicating a suitable PK-PD profile for a sleep-promoting drug, allowing for rapid onset and duration of action limited to the intended use. This comprehensive first-in-human study created a wealth of data, while saving resources in drug development.
© 2018 American Society for Clinical Pharmacology and Therapeutics.
Similar articles
-
Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration.J Psychopharmacol. 2020 Mar;34(3):326-335. doi: 10.1177/0269881119882854. Epub 2019 Oct 23. J Psychopharmacol. 2020. PMID: 31642731 Clinical Trial.
-
Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration.Eur Neuropsychopharmacol. 2019 Jul;29(7):847-857. doi: 10.1016/j.euroneuro.2019.05.009. Epub 2019 Jun 17. Eur Neuropsychopharmacol. 2019. PMID: 31221502 Clinical Trial.
-
Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass Spectrometry.Curr Drug Metab. 2019;20(4):254-265. doi: 10.2174/1389200220666190206141814. Curr Drug Metab. 2019. PMID: 30727881 Clinical Trial.
-
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders.Expert Opin Drug Metab Toxicol. 2020 Nov;16(11):1063-1078. doi: 10.1080/17425255.2020.1817380. Epub 2020 Oct 4. Expert Opin Drug Metab Toxicol. 2020. PMID: 32901578 Review.
-
Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.Drugs Today (Barc). 2016 Jan;52(1):29-40. doi: 10.1358/dot.2016.52.1.2439940. Drugs Today (Barc). 2016. PMID: 26937493 Review.
Cited by
-
Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.Clin Pharmacokinet. 2021 Oct;60(10):1349-1360. doi: 10.1007/s40262-021-01028-8. Epub 2021 May 18. Clin Pharmacokinet. 2021. PMID: 34002356 Clinical Trial.
-
Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects.Drugs R D. 2024 Mar;24(1):97-108. doi: 10.1007/s40268-024-00456-8. Epub 2024 Mar 13. Drugs R D. 2024. PMID: 38472696 Free PMC article. Clinical Trial.
-
Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data.Front Pharmacol. 2022 Mar 30;13:812065. doi: 10.3389/fphar.2022.812065. eCollection 2022. Front Pharmacol. 2022. PMID: 35431953 Free PMC article.
-
Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects.Clin Drug Investig. 2023 Nov;43(11):827-837. doi: 10.1007/s40261-023-01310-6. Epub 2023 Oct 19. Clin Drug Investig. 2023. PMID: 37858005
-
Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia.Psychopharmacology (Berl). 2021 Oct;238(10):2693-2708. doi: 10.1007/s00213-021-05954-0. Epub 2021 Aug 20. Psychopharmacology (Berl). 2021. PMID: 34415378 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
